Cadrenal Therapeutics 报告称，季度亏损大于预期，影响了股票表现。 Cadrenal Therapeutics reports a larger-than-expected quarterly loss, impacting stock performance.

一家生物制药公司Cadrenal治疗公司(NASDAQ:CVKD)报告每季度每股损失2.74美元,分析员预期损失1.03美元。 Cadrenal Therapeutics (NASDAQ: CVKD), a biopharmaceutical company, reported a quarterly loss of $2.74 per share, missing analyst expectations by $1.03. 股票开放额为19.09美元,市场上限为3 404万美元,P/E比率为-2.86,贝塔为1.40。 The stock opened at $19.09, with a market cap of $34.04 million, a P/E ratio of -2.86, and a beta of 1.40. 该公司的重点是开发Tecarfarin,这是预防心血管病罕见患者心脏病发作和中风的抗coaguant剂。 The company focuses on developing Tecarfarin, an anticoagulant to prevent heart attacks and strokes in patients with rare cardiovascular conditions.